Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC). Update February 2022

Wolf, S. (2021): Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC). Update February 2022. Oncology Fact Sheet Nr. 64.

[thumbnail of Oncology Fact Sheet Nr.64_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
705kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WP Gynaecology > WP 800-910 Breast
Language:	English
Series Name:	Oncology Fact Sheet Nr. 64
Deposited on:	15 Oct 2021 15:18
Last Modified:	10 Jul 2025 11:32

Repository Staff Only: item control page